Eagle Strategies’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
Other funds holding ABBV
Eagle Strategies's ABBV Position: Q2 2026 in Review
Eagle Strategies increased its AbbVie (ABBV) stake by 56% in Q2 2026, buying an estimated $252K and bringing the position to 3,262 shares worth $821K. The position accounts for 0.08% of the portfolio, ranked #158.
Eagle Strategies first reported a position in ABBV in Q3 2022 and has held it in 16 quarters since. The position peaked at $2.09M in Q1 2024. 2,236 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- Eagle Strategies held 3,262 shares of AbbVie worth $821K as of Q2 2026.
- Eagle Strategies bought 1,172 AbbVie shares in Q2 2026, an estimated $252K.
- AbbVie made up 0.08% of Eagle Strategies's portfolio in Q2 2026, its #158 holding.
- Eagle Strategies first reported a position in AbbVie in Q3 2022 and has held it in 16 quarters since.
- Eagle Strategies's AbbVie position peaked at $2.09M in Q1 2024.
- 2,236 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on Eagle Strategies's 13F filing for Q2 2026, filed 21 Jul 2026.